Back to Network
3
Shared Docs
3
Same-Page
3 / 3
Mentions
Document Mentions (3 shared documents)
2 mentions1 same-page
Page ?Same page
ER TX inhibitors became resistant from a single mutation of the protein T790M within the EGER kinase domain. PED's work caught the attention of Ile. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Universi
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
2 mentions1 same-page
Page ?Same page
ER TX inhibitors became resistant from a single mutation of the protein T790M within the EGER kinase domain. PED's work caught the attention of Ile. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Universi
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
2 mentions1 same-page
Page ?Same page
FR TK inhibitors became resistant from a single mutation of the protein T790M within the EGFR kinase domain. PED's work caught the attention of Dr. Bert Vogelstein, the Director of the Ludwig Center for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific, inhibitor drugs to fight cancer has been growing in popularity around the wor
Sponsored
Mutual Connections (14)
Entities connected to both Bert Vogelstein and The Final Frontier
Martin Nowak
PERSON10 w/ Bert·4 w/ The
Jeffrey Epstein
PERSON9 w/ Bert·4 w/ The
the Program for Evolutionary Dynamics
ORGANIZATION4 w/ Bert·4 w/ The
VO
Vogelstein
PERSON3 w/ Bert·4 w/ The
Johns Hopkins University School of Medicine
ORGANIZATION3 w/ Bert·4 w/ The
the National Institute of Cancer
ORGANIZATION3 w/ Bert·4 w/ The
Massachusetts General
ORGANIZATION2 w/ Bert·3 w/ The
NE
Nenvak
PERSON2 w/ Bert·2 w/ The
Journal of Oncology
ORGANIZATION2 w/ Bert·2 w/ The
a Biology and Mathematics
ORGANIZATION2 w/ Bert·2 w/ The
Johns I Iopkins
ORGANIZATION2 w/ Bert·2 w/ The
trials pandit&
ORGANIZATION2 w/ Bert·2 w/ The
ET
EGER TX
PERSON2 w/ Bert·2 w/ The
TG
the lYinzetor of the Ludwig Center for Cancer Genetics
PERSON2 w/ Bert·2 w/ The